Oracle has introduced Oracle Life Sciences AI Agents, an agentic layer for clinical trial operations. The agents pull together data from Oracle’s life sciences applications and supported third-party sources, watch how studies are performing, flag operational problems and recommend next steps. A human has to review and approve every proposed action before it runs.
Quick Take
- What it is: AI agents for clinical trial operations, covering portfolio monitoring, trial planning and trial conduct.
- What they do: Monitor study performance, identify likely drivers of KPI variances and recommend operational actions that follow the trial protocol.
- Human control: Humans review recommendations and approve proposed actions before execution.
- Availability: Available now for early adopters.
- Next: Oracle plans to extend the agents to clinical data management, post-trial analytics, trial design and post-market workflows.
In plain English
Running a drug trial means tracking dozens of sites, patients, deadlines and data feeds at once. When a site falls behind on enrolment or data entry, teams often notice late. Oracle’s agents are meant to spot such problems early, explain what is likely causing them and suggest what to do, while people stay in charge of the decision.
What happened
Oracle announced the agents on November 18 in Austin, Texas. It describes them as an agentic experience that helps clinical teams identify operational issues, recommend actions for review and approval, and coordinate responses across clinical development workflows. As an example, Oracle says an agent can monitor study performance and the likely drivers of KPI variances, then recommend actions in line with the trial protocol.
“We are bringing AI-assisted intelligence into clinical trial operations to help organizations to monitor performance, identify emerging risks, and coordinate responses across the trial lifecycle,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences.
Background
Oracle already sells widely used software for clinical trials and safety, so adding agents on top of its own applications gives it direct access to the data those agents need. The launch fits a broader wave of agentic tools aimed at health care operations rather than diagnosis, such as ElevenLabs’ medical voice agents and agents for insurance and scheduling work.
Why it matters
Clinical trials are slow and expensive, and many delays come from operations, not science: slow sites, missed data and poor coordination. If agents can surface those problems earlier, trials could run faster and cheaper. Keeping humans as approvers matters in a field governed by strict protocols and regulators.
What’s still open
- Which sponsors and research organisations are among the early adopters.
- How much time or cost the agents actually save in live trials.
- When the planned expansion into data management and trial design arrives.
About the analysis
This independent i10x analysis is based on Oracle’s press release. The quote is taken from that source.
Sources (plain text, no links):
- Oracle press release: “Oracle Life Sciences AI Agents Bring AI-Assisted Operational Intelligence and Coordination to Clinical Trials” (November 18, 2026)
i10x Perspective
Pharma is unlikely to let AI make trial decisions anytime soon, but it will gladly let AI do the watching. Operations agents with a human sign-off are the realistic first step for AI in drug development. Follow more on our Health & Medical Research page and in the State of AI in Health report.



